Skip to content

Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee

CompletedPhase 3NCT00988091
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Subjects with chronic osteoarthritis of the knee will be assigned to receive an injection of either 1.2% sodium hyaluronate or buffered saline to evaluate its effectiveness and safety for 26 weeks. After 26 weeks, subjects can elect to receive a second injection of 1.2% sodium hyaluronate and be followed for another 26 weeks.

Study details

Official title
A 26 Week, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Single Intra-Articular Injection 1.2% Sodium Hyaluronate for Treatment of Painful Osteoarthritis of the Knee, With Optional 26-Week Open-Label Safety Extension
Interventions
  • Device: 1.2% Sodium Hyaluronate
  • Device: Buffered Saline
Sponsor
Ferring Pharmaceuticals
Start date
2009-09
Primary completion
2010-10
Sex
All
Age range
from 40 Years
Results posted
Yes, on ClinicalTrials.gov
Countries
United States
Total sites listed
34

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic osteoarthritis (OA) of target knee confirmed by American College of Rheumatology (ACR) Criteria. * Pain due to OA in target knee present for at least 6 months. * During Screening and Baseline visits, subjects will require a visual analog scale (VAS) score (100 mm) of ≥ 41 mm and ≤ 90 mm, recorded immediately following a 50-foot walk, AND at Baseline, cannot have decreased \>10mm (improvement) from Screening. * A bilateral standing anteroposterior (AP) X-ray confirming OA of the target knee. * Ability and willingness to use only acetaminophen as the analgesic (rescue) study medication * Ability to perform procedures required of the pain index evaluations (unassisted walking 50 feet on a flat surface and going up and down stairs). * Willingness and ability to complete efficacy and safety questionnaires and ability to read and understand study instructions. * Signed Subject Informed Consent Form Exclusion Criteria: * Any major injury (including sports injuries) to the target knee within the prior 12 months. * Any surgery to the target knee, hip and contralateral hip within the prior 12 months. * Major and minor articular procedures * Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or psoriatic arthritis. * Gout or calcium pyrophosphate (pseudogout) diseases of the target knee that have flared within the previous 6 months. * X-ray findings of acute fractures, severe loss of bone density, avascular necrosis, and/or severe bone or joint deformity in the target knee. * Osteonecrosis of either knee. * Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or vascular claudication. * Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia in the target knee. * Significant target knee joint infection or skin disorder/infection within the previous 6 months prior to study enrollment. * Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation of the target knee. * Known hypersensitivity to acetaminophen, sodium hyaluronate, or phosphate buffered saline solution. * Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period. * Recurrent medical history of severe allergic or immune-mediated reactions or other immune disorders. * Vascular insufficiency of lower limbs or periphera…

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00988091